The new treatment for alopecia areata approved in 2024 is deuruxolitinib.
Deuruxolitinib (LEQSELVI®): A New Hope for Alopecia Areata
In July 2024, the FDA approved deuruxolitinib (LEQSELVI®) as a treatment for adults (18 years and older) suffering from alopecia areata. This represents the third JAK inhibitor approved for this condition.
Key Facts about LEQSELVI®:
- Type: Oral medication.
- Dosage: Taken two times per day.
- Indication: Alopecia areata in adults.
- Approval Date: July 2024.
- Mechanism: JAK inhibitor.
What is Alopecia Areata?
Alopecia areata is an autoimmune disorder that causes hair loss. This can affect the scalp, face, and other parts of the body. The condition can be emotionally distressing and significantly impact a person's quality of life.
How Does Deuruxolitinib Work?
Deuruxolitinib belongs to a class of drugs known as Janus kinase (JAK) inhibitors. These medications work by blocking the activity of specific enzymes called Janus kinases, which are involved in inflammation and immune responses. By inhibiting these enzymes, deuruxolitinib helps to reduce the inflammation that contributes to hair loss in alopecia areata.
Other Alopecia Areata Treatments:
While deuruxolitinib is a new treatment option, it is not the only one available. Other treatments include:
- Topical corticosteroids: Reduce inflammation on the scalp.
- Minoxidil: Can help stimulate hair growth.
- Other JAK inhibitors: Ritlecitinib (LITFULO™) and baricitinib (OLUMIANT®)
Here's a quick comparison in a table format:
| Treatment | Type | Administration | Approval Date |
|---|---|---|---|
| Deuruxolitinib (LEQSELVI®) | Oral JAK Inhibitor | Twice Daily | July 2024 |
| Ritlecitinib (LITFULO™) | JAK Inhibitor | Oral | |
| Baricitinib (OLUMIANT®) | JAK Inhibitor | Oral |
Conclusion
The FDA approval of deuruxolitinib (LEQSELVI®) represents a significant advancement in the treatment of alopecia areata, offering a new oral option for adults seeking to manage their condition.
